| Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma MP Chao, AA Alizadeh, C Tang, JH Myklebust, B Varghese, S Gill, M Jan, ... Cell 142 (5), 699-713, 2010 | 1223 | 2010 |
| Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia M Jan, TM Snyder, MR Corces-Zimmerman, P Vyas, IL Weissman, ... Science translational medicine 4 (149), 149ra118-149ra118, 2012 | 873 | 2012 |
| Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia MP Chao, AA Alizadeh, C Tang, M Jan, R Weissman-Tsukamoto, F Zhao, ... Cancer research 71 (4), 1374-1384, 2011 | 467 | 2011 |
| COPA mutations impair ER-Golgi transport and cause hereditary autoimmune-mediated lung disease and arthritis LB Watkin, B Jessen, W Wiszniewski, TJ Vece, M Jan, Y Sha, M Thamsen, ... Nature genetics 47 (6), 654-660, 2015 | 378 | 2015 |
| Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker M Jan, MP Chao, AC Cha, AA Alizadeh, AJ Gentles, IL Weissman, ... Proceedings of the National Academy of Sciences 108 (12), 5009-5014, 2011 | 335 | 2011 |
| The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K M Słabicki, Z Kozicka, G Petzold, YD Li, M Manojkumar, RD Bunker, ... Nature 585 (7824), 293-297, 2020 | 328 | 2020 |
| CAR T cell killing requires the IFNγR pathway in solid but not liquid tumours RC Larson, MC Kann, SR Bailey, NJ Haradhvala, PM Llopis, AA Bouffard, ... Nature 604 (7906), 563-570, 2022 | 271 | 2022 |
| Reversible ON-and OFF-switch chimeric antigen receptors controlled by lenalidomide M Jan, I Scarfò, RC Larson, A Walker, A Schmidts, AA Guirguis, JA Gasser, ... Science translational medicine 13 (575), eabb6295, 2021 | 219 | 2021 |
| Clonal evolution of acute leukemia genomes M Jan, R Majeti Oncogene 32 (2), 135-140, 2013 | 188 | 2013 |
| Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma NJ Haradhvala, MB Leick, K Maurer, SH Gohil, RC Larson, N Yao, ... Nature medicine 28 (9), 1848-1859, 2022 | 159 | 2022 |
| The evolutionarily conserved longevity determinants HCF-1 and SIR-2.1/SIRT1 collaborate to regulate DAF-16/FOXO G Rizki, TN Iwata, J Li, CG Riedel, CL Picard, M Jan, CT Murphy, SS Lee PLoS genetics 7 (9), e1002235, 2011 | 137 | 2011 |
| Clonal hematopoiesis M Jan, BL Ebert, S Jaiswal Seminars in hematology 54 (1), 43-50, 2017 | 135 | 2017 |
| Cancer therapies based on targeted protein degradation—lessons learned with lenalidomide M Jan, AS Sperling, BL Ebert Nature Reviews Clinical Oncology 18 (7), 401-417, 2021 | 101 | 2021 |
| Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemia MB Leick, H Silva, I Scarfò, R Larson, BD Choi, AA Bouffard, K Gallagher, ... Cancer cell 40 (5), 494-508. e5, 2022 | 96 | 2022 |
| Clonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapy PG Miller, AS Sperling, EJ Brea, MB Leick, GG Fell, M Jan, SH Gohil, ... Blood advances 5 (15), 2982-2986, 2021 | 88 | 2021 |
| Clonal hematopoiesis is associated with protection from Alzheimer’s disease H Bouzid, JA Belk, M Jan, Y Qi, C Sarnowski, S Wirth, L Ma, MR Chrostek, ... Nature Medicine 29 (7), 1662-1670, 2023 | 86 | 2023 |
| Recurrent genetic HLA loss in AML relapsed after matched unrelated allogeneic hematopoietic cell transplantation M Jan, MJ Leventhal, EA Morgan, JC Wengrod, A Nag, SD Drinan, ... Blood Advances 3 (14), 2199-2204, 2019 | 73 | 2019 |
| Patterns of substrate affinity, competition, and degradation kinetics underlie biological activity of thalidomide analogs AS Sperling, M Burgess, H Keshishian, JA Gasser, S Bhatt, M Jan, ... Blood, The Journal of the American Society of Hematology 134 (2), 160-170, 2019 | 65 | 2019 |
| Proteolysis-targeting chimeras with reduced off-targets TM Nguyen, V Sreekanth, A Deb, P Kokkonda, PK Tiwari, KA Donovan, ... Nature chemistry 16 (2), 218-228, 2024 | 38 | 2024 |
| Efficacy and Safety of Dasatinib in Patients with Chronic Myeloid Leukemia in Blast Phase Whose Disease Is Resistant or Intolerant to Imatinib: 2-Year Follow-Up Data from the … C Gambacorti, J Cortes, DW Kim, H Dombret, C Zhu, JMA Van Tornout, ... Blood 110 (11), 472, 2007 | 30 | 2007 |
